Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594161 | 0.87 | GCK (0.40) | KMT2AMEN1NPC1POLBCYP2C9 | |
| SCHEMBL3603264 | 0.84 | PLA2G2A (0.35) | KMT2AMEN1NPC1POLBCYP2C9 | |
| SCHEMBL3598649 | 0.83 | PLA2G2A (0.32) | — | |
| SCHEMBL3586994 | 0.80 | MEN1 (0.47) | KMT2AMEN1MRGPRX4 | |
| SCHEMBL3605126 | 0.80 | PLA2G2A (0.40) | KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL3605804 | 0.74 | PLA2G2A (0.35) | KMT2AMEN1NPC1POLBRAB9A | |
| SCHEMBL17060024 | 0.72 | PLA2G2A (0.46) | KMT2AMEN1CYP2C9KDM4E | |
| SCHEMBL10941156 | 0.71 | KCNN4 (0.40) | — | |
| SCHEMBL3592397 | 0.70 | KMT2A (0.45) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3595570 | 0.70 | GCK (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700640-B2 | Process for making phenoxy benzamide compounds | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| EP-1802570-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040527-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | PAH, MAOB, TYR | KMT2A 726/4885MEN1 2346/4885NPC1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.